A5020353618- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Melanoma and MAPK Pathways
- Cancer Mechanisms and Therapy
- 14-3-3 protein interactions
- Microbial Metabolic Engineering and Bioproduction
- Lanthanide and Transition Metal Complexes
- Acute Kidney Injury Research
- Cancer Genomics and Diagnostics
- Bioinformatics and Genomic Networks
- Cardiac, Anesthesia and Surgical Outcomes
- Protein Kinase Regulation and GTPase Signaling
- Ubiquitin and proteasome pathways
- PI3K/AKT/mTOR signaling in cancer
- Gene Regulatory Network Analysis
- Cerebrovascular and Carotid Artery Diseases
- Traumatic Brain Injury and Neurovascular Disturbances
- Protein Tyrosine Phosphatases
Icahn School of Medicine at Mount Sinai
2002-2023
Illumina (United States)
2018
Mount Sinai Hospital
2003
Mount Sinai Hospital
2002
While gene expression data at the mRNA level can be globally and accurately measured, profiling activity of cell signaling pathways is currently much more difficult.eXpression2Kinases (X2K) computationally predicts involvement upstream pathways, given a signature differentially expressed genes.X2K first computes enrichment for transcription factors likely to regulate genes.The next step X2K connects these enriched through known protein-protein interactions (PPIs) construct subnetwork.The...
The approved kinase inhibitors for hepatocellular carcinoma (HCC) are not matched to specific mutations within tumors. This has presented a daunting challenge; without clear target or mechanism, no straightforward path existed guide the development of improved therapies HCC. Here, we combine phenotypic screens with class conformation-specific termed type II identify multikinase inhibitor, AD80, antitumoral activity across variety HCC preclinical models, including mouse xenografts. Mass...
Abstract Purpose: We recently developed a chemical strategy for the diversification and disease-specific improvement of tool FDA-approved kinase inhibitors, sought to use this genotype-specific drug discovery in hepatocellular carcinoma (HCC). Experimental Procedures: Primary murine-derived HCC organoids were used screening. Expansive multiomic (phosphoproteomics, RNAseq, ChIPseq) target engagement analyses combination with vitro rescue vivo efficacy experiments. Data Summary: Currently...